Targeting HR pathways offers potential therapeutic avenues, especially in cancer treatment. PARP inhibitors are a class of drugs that exploit HR deficiencies in cancer cells, leading to synthetic lethality. These inhibitors prevent the repair of single-strand breaks, which convert into toxic DSBs in HR-deficient cells, selectively killing them. As such, understanding HR mechanisms provides insights into developing drugs that enhance the efficacy of existing therapies.
